Journal
British Journal of Haematology
Publication Date
2018
Volume
180
Inclusive Pages
821-830
Document Type
Open Access Publication
DOI
10.1111/bjh.15058
Rights and Permissions
Richardson, P. G., Bensinger, W. I., Huff, C. A., Costello, C. L., Lendvai, N. , Berdeja, J. G., Anderson, L. D., Siegel, D. S., Lebovic, D. , Jagannath, S. , Laubach, J. P., Stockerl‐Goldstein, K. E., Kwei, L. , Clow, F. , Elias, L. , Salman, Z. , Graef, T. , Bilotti, E. and Vij, R. (2018), Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. Br J Haematol, 180: 821-830. doi:10.1111/bjh.15058 © 2018 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Recommended Citation
Stockerl-Goldstein, Keith E.; Vij, Ravi; and et al, "Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: Phase 2 trial results." British Journal of Haematology. 180, 821-830. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7660
